<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004904</url>
  </required_header>
  <id_info>
    <org_study_id>NU FDA97H1</org_study_id>
    <secondary_id>NU-97H1</secondary_id>
    <secondary_id>NCI-G00-1691</secondary_id>
    <nct_id>NCT00004904</nct_id>
  </id_info>
  <brief_title>Stem Cell Transplantation in Treating Patients With Hematologic Cancer</brief_title>
  <official_title>Phase I Study of T Cell Depleted (TCD) Partially Matched Related Donor (PMRD) Hematopoietic Stem Cell Transplantation for High Risk Hematologic Diseases Using Intense Pre and Post Transplant Immunosuppression and Megadose CD34 &quot;Veto&quot; Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were
      destroyed by chemotherapy and radiation therapy used to kill tumor cells.

      PURPOSE: Phase I trial to study the effectiveness of treated donor stem cell transplantation
      in treating patients who have hematologic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine if megadose CD34 cells and intense immunosuppression administered
      before and after partially matched related donor (PMRD) hematopoietic stem cell (HSC)
      transplantation results in engraftment in patients with high risk hematologic malignancies.
      II. Determine the incidence and severity of acute grade (I-IV) and chronic (limited or
      extensive) graft versus host disease in patients after rigorous T-cell depletion in PMRD HSC
      transplantation.

      OUTLINE: Harvest: Bone marrow and peripheral blood stem cells (PBSC) are harvested from a
      related 1, 2, or 3 HLA antigen mismatched donor. PBSC are selected for CD34+ cells and
      T-cells are depleted. Conditioning: Patients undergo total body irradiation twice daily on
      days -10 to -7 and once on day -6. Patients receive cladribine IV continuously on days -10 to
      -6; etoposide IV over 2 hours on day -5; and cyclophosphamide IV over 2 hours, antithymocyte
      globulin (ATG) IV over 10-12 hours, and methylprednisolone IV over 1 hour on days -4 to -2.
      Transplantation: T-cell depleted PBSC and bone marrow are infused on day 0. Patients receive
      G-CSF SQ daily beginning on day 0 and continuing until blood counts recover. Graft versus
      host disease prophylaxis: Patients receive tacrolimus IV every 12 hours beginning on day -2
      and continuing orally 4 times a day for 6-12 months at the discretion of the protocol
      investigator. Patients receive ATG IV over 10-12 hours and methylprednisolone IV over 1 hour
      on days 5-15 followed by a taper of methylprednisolone. Patients are followed every week
      through day 100 and then at 6 and 12 months.

      PROJECTED ACCRUAL: A total of 12-20 patients will be accrued for this study within 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1999</start_date>
  <completion_date type="Actual">July 2000</completion_date>
  <primary_completion_date type="Actual">July 2000</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Graft Versus Host Disease</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Precancerous/Nonmalignant Condition</condition>
  <condition>Small Intestine Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cladribine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>in vitro-treated peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven hematologic malignancy with relapse after
        allogeneic bone marrow transplantation (BMT) or autologous BMT if no HLA matched sibling
        donor is available OR Histologically proven acute myeloid leukemia (AML) without an
        available HLA matched sibling donor and with one of the following: Failure of induction,
        defined as inability to obtain remission with 2 courses of induction or failure during
        treatment Second or greater remission OR Histologically proven acute lymphocytic leukemia
        (ALL) in an adult over age 15 without an available HLA matched sibling donor and with one
        of the following: Philadelphia chromosome positivity by cytogenetics or PCR Relapse or
        second or greater remission Two or more prognostic features (over age 30, WBC on
        presentation over 35,000/mm3, time to complete response over 4 weeks, t(4:11), or B-cell
        ALL) OR Histologically proven chronic myelogenous leukemia In chronic phase without an A,
        B, and DR unrelated matched donor OR In accelerated phase, defined as new cytogenetic
        abnormalities or difficulty maintaining a normal WBC due to dose limiting cytopenias
        (thrombocytopenias or anemia) from hydroxyurea or interferon OR In blast transformation OR
        Histologically proven aplastic anemia without an available HLA matched sibling donor and
        failure of an immunosuppressive therapy regimen using either cyclosporine, antithymocyte
        globulin, or both OR Histologically proven lymphoma without an available HLA matched donor
        and failure of at least 2 different chemotherapy regimens OR Histologically proven
        cutaneous T-cell lymphoma without an available HLA matched donor and failure of interferon
        and PUVA (psoralen and ultraviolet A radiation) OR Histologically proven myelodysplastic
        syndrome without an available HLA matched sibling donor and with one of the following: 5%
        or greater blasts in marrow Multiple cytogenetic abnormalities History of infections from
        neutropenia 1, 2, or 3 antigen mismatched related donor available

        PATIENT CHARACTERISTICS: Age: Physiologic age 45 and under Performance status: ECOG 0-2
        Life expectancy: Not specified Hematopoietic: See Disease Characteristics Hepatic:
        Bilirubin no greater than 2.0 mg/dL SGOT and SGPT no greater than 2 times upper limit of
        normal Renal: Creatinine no greater than 2.0 mg/dL Cardiovascular: No myocardial infarction
        within the past 6 months No coronary artery disease requiring medical therapy Resting LVEF
        at least 40% Pulmonary: FEV1/FVC at least 60% predicted DLCO at least 60% predicted Other:
        HIV negative No prior malignancy except basal cell or squamous cell skin cancer Other
        malignancies for which the patient is cured by local surgical therapy, such as head and
        neck cancer or stage I breast cancer, are considered on an individual basis Not pregnant
        Negative pregnancy test Fertile patients must use effective contraception No psychiatric
        illness or mental deficiency that would preclude compliance or informed consent

        PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Chemotherapy: See
        Disease Characteristics Endocrine therapy: Not specified Radiotherapy: Not specified
        Surgery: Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard K. Burt, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Robert H. Lurie Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center, Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-3013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2000</study_first_submitted>
  <study_first_submitted_qc>March 2, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2004</study_first_posted>
  <last_update_submitted>May 31, 2012</last_update_submitted>
  <last_update_submitted_qc>May 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>monoclonal gammopathy of undetermined significance</keyword>
  <keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>isolated plasmacytoma of bone</keyword>
  <keyword>extramedullary plasmacytoma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>Waldenstrom macroglobulinemia</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>small intestine lymphoma</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>polycythemia vera</keyword>
  <keyword>chronic idiopathic myelofibrosis</keyword>
  <keyword>essential thrombocythemia</keyword>
  <keyword>refractory hairy cell leukemia</keyword>
  <keyword>T-cell large granular lymphocyte leukemia</keyword>
  <keyword>acute undifferentiated leukemia</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>stage III adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>graft versus host disease</keyword>
  <keyword>primary systemic amyloidosis</keyword>
  <keyword>intraocular lymphoma</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Cladribine</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

